- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00000485
Programa de Detección y Seguimiento de la Hipertensión Arterial (HDFP)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
ANTECEDENTES:
Los datos publicados del Estudio Cooperativo de Hipertensión de la Administración de Veteranos demostraron que se podría lograr una reducción en la morbilidad y la mortalidad al tratar a los hombres con presión arterial diastólica fija superior a 105 mm Hg. Ocurrieron tendencias similares para aquellos con presión arterial diastólica fija entre 90 y 104 mm Hg. Los resultados y las tendencias actuales de otros estudios respaldaron estos hallazgos. Sin embargo, antes del inicio del Programa de Detección y Seguimiento de la Hipertensión (HDFP), no se sabía si los beneficios de la terapia antihipertensiva aplicada a todos los hipertensos en la población general y si haciendo uso del conocimiento médico existente podría reducir significativamente la morbilidad y la mortalidad por hipertensión en las comunidades.
Al reconocer esta necesidad, el NHLBI inició las actividades piloto del HDFP para caracterizar los factores operativos, socioeconómicos y motivacionales significativos que influirían en la aceptación de la terapia antihipertensiva en las poblaciones definidas dentro de las cuales se llevaría a cabo el ensayo clínico controlado y para obtener la información de referencia necesaria para la realización del ensayo clínico, cuyo objetivo era determinar si un programa práctico, intensivo y antihipertensivo podría reducir significativamente la morbimortalidad de los hipertensos en la población general.
La planificación del ensayo, incluida la elaboración de un protocolo y manual de operaciones, comenzó en 1971. Entre febrero de 1973 y mayo de 1974, 158.906 personas fueron examinadas para la presión arterial alta en 14 comunidades. Se asignó al azar un total de 10 940 participantes hipertensos.
La hipótesis principal probada por el ensayo fue que el control intensivo de la presión arterial bajo atención escalonada durante cinco años podría reducir significativamente la mortalidad en comparación con la atención remitida. La atención escalonada fue el método de tratamiento en las clínicas de HDFP en las que inicialmente se administró un diurético y se agregaron agentes antihipertensivos adicionales en forma escalonada y estructurada en el tiempo hasta que se logró la presión arterial objetivo. La atención referida representaba la referencia a médicos privados y otras fuentes comunitarias de atención. En este estudio participaron 14 centros clínicos, un centro coordinador, un centro de ECG, un laboratorio central y un laboratorio de monitoreo.
La fase clínica del ensayo finalizó en mayo de 1982. El proyecto se prorrogó hasta 1983 para continuar con la vigilancia de la mortalidad y el control de la presión arterial.
NARRATIVA DE DISEÑO:
El ensayo fue un ensayo aleatorio, no ciego, de muestra fija con una sola intervención y grupos de control. El grupo de intervención recibió atención escalonada de las clínicas de ensayos clínicos (ver Antecedentes, a continuación), mientras que los del grupo de control fueron derivados a sus propios médicos. Cada comunidad contribuyó con participantes de atención escalonada y atención referida, pero para fines de análisis, los grupos se agruparon en dos grupos. El punto final primario fue la mortalidad. Los efectos de la atención escalonada frente a la atención referida también se evaluaron en factores intermedios y secundarios, incluidos los códigos nosológicos de causas específicas de mortalidad, infarto de miocardio no fatal, accidente cerebrovascular, enfermedad cardíaca hipertensiva y anomalías en el ECG.
Tipo de estudio
Fase
- Fase 3
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
Colaboradores e Investigadores
Patrocinador
Investigadores
- C. Hawkins, University of Texas
Publicaciones y enlaces útiles
Publicaciones Generales
- Remington RD On behalf of the HDFP Cooperative Group: The Hypertension Detection and Follow-up Program. Inserm, 21:185-194, 1973.
- Mild hypertensives in the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Cooperative Group. Ann N Y Acad Sci. 1978 Mar 30;304:254-66. doi: 10.1111/j.1749-6632.1978.tb25603.x. No abstract available.
- Patient participation in a hypertension control program. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1978 Apr 14;239(15):1507-14.
- Variability of blood pressure and the results of screening in the hypertension detection and follow-up program. J Chronic Dis. 1978;31(11):651-67. doi: 10.1016/0021-9681(78)90069-3. No abstract available.
- Hypertension and Education. Journal of the American Dietetic Association, 72 (4):377, April l978. (Summary of Mainstream Paper #5A.)
- Blood Pressure Studies in l4 Communities: A Two-Stage Screen for Hypertension. l978 Year Book of Cardiology: 355-57 (Summary of Mainstream Paper #2.)
- Therapeutic control of blood pressure in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group. Prev Med. 1979 Jan;8(1):2-13. doi: 10.1016/0091-7435(79)90024-0. No abstract available.
- Borhani N: The Hypertension Detection and Follow-Up Program, in Onesti G and Klimt C (eds), Hypertension. Determinants, Complications, and Intervention, Grune & Stratton, New York, pp. 405-4l4, l979.
- Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979 Dec 7;242(23):2562-71.
- Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979 Dec 7;242(23):2572-7. doi: 10.1001/jama.1979.03300230028022.
- Wassertheil-Smoller S, Apostolides A, Miller M, Oberman A, Thom T. Recent status of detection, treatment, and control of hypertension in the community. J Community Health. 1979 Winter;5(2):82-93. doi: 10.1007/BF01324010.
- Apostolides AY, Cutter G, Kraus JF, Oberman A, Blaszkowski T, Borhani NO, Entwisle G. Impact of hypertension information on high blood pressure control between 1973 and 1978. Hypertension. 1980 Sep-Oct;2(5):708-13. doi: 10.1161/01.hyp.2.5.708.
- Cutter G, Heyden S, Kasteler J, Kraus JF, Lee ES, Shipley T, Stromer M. Mortality surveillance in collaborative trials. Am J Public Health. 1980 Apr;70(4):394-400. doi: 10.2105/ajph.70.4.394.
- Cowan L, Detels R, Farber M, Lee ES, McCray G, O'Flynn S, Parnell MJ. Residential mobility and long-term treatment of hypertension. J Community Health. 1980 Spring;5(3):159-66. doi: 10.1007/BF01323988.
- Stamler J, Borhani NO: Interview: HDFP Mortality and Morbidity. Hypertension Report, 1(l):l2-l4, l980.
- Stamler J: Clinical Ramifications of the Hypertension Detection and Follow-up Program: Benefits of Treatment Outweigh Risks. Symposia Reporter, 4(2):l2-l4, May l980.
- Langford HG: Clinical Ramifications of the Hypertension Detection and Follow-up Program: HDFP Methodology and Results: Overview. Symposia Reporter, 4(2):3-6, May l980.
- Borhani NO: Clinical Ramifications of the Hypertension Detection and Follow-up Program: SC Yields Lower Mortality and Morbidity. Symposia Reporter, 4(2):l6, May l980.
- Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1982 Feb 5;247(5):633-8.
- Apostolides AY, Cutter G, Daugherty SA, Detels R, Kraus J, Wassertheil-Smoller S, Ware J. Three-year incidence of hypertension in thirteen U.S. communities. On behalf of the Hypertension Detection and Follow-up Program cooperative group. Prev Med. 1982 Sep;11(5):487-99. doi: 10.1016/0091-7435(82)90063-9. No abstract available.
- Kraus JF, Conley A, Hardy R, Sexton M, Sweezy Z. Relationship of demographic characteristics of interviewers to blood pressure measurements. J Community Health. 1982 Fall;8(1):3-12. doi: 10.1007/BF01324392.
- Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. Hypertension. 1982 Mar-Apr;4(2):307-11. doi: 10.1161/01.hyp.4.2.307.
- Shulman N, Cutter G, Daugherty R, Sexton M, Pauk G, Taylor MJ, Tyler M. Correlates of attendance and compliance in the hypertension detection and follow-up program. Control Clin Trials. 1982 Mar;3(1):13-27. doi: 10.1016/0197-2456(82)90016-2.
- Smith EO, Curb JD, Hardy RJ, Hawkins CM, Tyroler HA. Clinic attendance in the hypertension detection and follow-up program. Hypertension. 1982 Sep-Oct;4(5):710-5. doi: 10.1161/01.hyp.4.5.710. No abstract available.
- Curb JD, Ford C, Hawkins CM, Smith EO, Zimbaldi N, Carter B, Cooper C. A coordinating center in a clinical trial: the Hypertension Detection and Followup Program. Control Clin Trials. 1983 Sep;4(3):171-86. doi: 10.1016/0197-2456(83)90001-6.
- Daugherty SA, Entwisle G, et al (Eds.): Hypertension Detection and Follow-Up Program: Baseline Characteristics of the Enumerated, Screened, and Hypertensive Participants. Hypertension (AHA Monograph No. 104), 1983.
- Hardy RJ, Hawkins CM. The impact of selected indices of antihypertensive treatment on all-cause mortality. Am J Epidemiol. 1983 May;117(5):566-74. doi: 10.1093/oxfordjournals.aje.a113579.
- Morris DL, Borhani NO, Fitzsimons E, Hardy RJ, Hawkins CM, Kraus JF, Labarthe DR, Mastbaum L, Payne GH. Serum cholesterol and cancer in the Hypertension Detection and Follow-up Program. Cancer. 1983 Nov 1;52(9):1754-9. doi: 10.1002/1097-0142(19831101)52:93.0.co;2-j.
- Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider K, Hames CG. Prediagnostic serum selenium and risk of cancer. Lancet. 1983 Jul 16;2(8342):130-4. doi: 10.1016/s0140-6736(83)90116-2.
- Tyroler HA: Race, Education and Five-Year Mortality In HDFP Stratum I Referred-care Males in Mild Hypertension: Recent Advances, Gross R and Strasser T (Eds). New York, Raven Press, 163- , 1983.
- Daugherty SA. Hypertension detection and follow-up program. Description of the enumerated and screened population. Hypertension. 1983 Nov-Dec;5(6 Pt 2):IV1-43. doi: 10.1161/01.hyp.5.6_pt_2.iv1. No abstract available.
- Taylor JO, Borhani NO, Entwisle G, Farber M, Hawkins CM. Hypertension detection and follow-up program. Summary of the baseline characteristics of the hypertensive participants. Hypertension. 1983 Nov-Dec;5(6 Pt 2):IV44-50. doi: 10.1161/01.hyp.5.6_pt_2.iv44. No abstract available.
- Kraus JF, Curb JD, Cutter G, Daugherty SA, Neill KC, Wassertheil-Smoller S. Hypertension detection and follow-up program. Baseline medical history characteristics of the hypertensive participants. Hypertension. 1983 Nov-Dec;5(6 Pt 2):IV51-91. doi: 10.1161/01.hyp.5.6_pt_2.iv51. No abstract available.
- Polk BF, Cutter G, Daugherty RM, Gosch F, Heyden S, Shulman N, Tyroler HA. Hypertension detection and follow-up program. Baseline physical examination characteristics of the hypertensive participants. Hypertension. 1983 Nov-Dec;5(6 Pt 2):IV92-132. doi: 10.1161/01.hyp.5.6_pt_2.iv92. No abstract available.
- Maxwell MH, Fitzsimmons E, Harrist R, Hotchkiss J, Langford HG, Payne GH, Schneider KA, Varaday P. Hypertension detection and follow-up program. Baseline laboratory examination characteristics of the hypertensive participants. Hypertension. 1983 Nov-Dec;5(6 Pt 2):IV133-59. doi: 10.1161/01.hyp.5.6_pt_2.iv133. No abstract available.
- Prineas RJ, Castle CH, Curb JD, Harrist R, Lewin A, Stamler J. Hypertension detection and follow-up program. Baseline electrocardiographic characteristics of the hypertensive participants. Hypertension. 1983 Nov-Dec;5(6 Pt 2):IV160-89. doi: 10.1161/01.hyp.5.6_pt_2.iv160. No abstract available.
- Oberman A, Blaufox MD, Entwisle G, Harrist R. Hypertension detection and follow-up program. Baseline chest radiographic characteristics of the hypertensive participants. Hypertension. 1983 Nov-Dec;5(6 Pt 2):IV190-200. doi: 10.1161/01.hyp.5.6_pt_2.iv190. No abstract available.
- Polk BF, Harlan LC, Cooper SP, Stromer M, Ignatius J, Mull H, Blaszkowski TP. Disability days associated with detection and treatment in a hypertension control program. Am J Epidemiol. 1984 Jan;119(1):44-53. doi: 10.1093/oxfordjournals.aje.a113724.
- Willett WC, Polk BF, Underwood BA, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider K, Hames CG. Relation of serum vitamins A and E and carotenoids to the risk of cancer. N Engl J Med. 1984 Feb 16;310(7):430-4. doi: 10.1056/NEJM198402163100705.
- Langford HG, Oberman A, Borhani NO, Entwisle G, Tung B. Black-white comparison of indices of coronary heart disease and myocardial infarction in the stepped-care cohort of the Hypertension Detection and Follow-Up Program. Am Heart J. 1984 Sep;108(3 Pt 2):797-801. doi: 10.1016/0002-8703(84)90674-4.
- The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. The Hypertension Detection and Follow-up Program Cooperative Research Group. Circulation. 1984 Dec;70(6):996-1003. doi: 10.1161/01.cir.70.6.996.
- Five-year findings of the Hypertension Detection and Follow-up Program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1985 Jan-Feb;7(1):105-12.
- Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Patient-perceived side effects to antihypertensive drugs. Am J Prev Med. 1985 Jan-Feb;1(1):36-40.
- Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985 Jun 14;253(22):3263-8.
- Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-Year findings of the hypertension detection and follow-up program. Hypertension. 1984 Mar-Apr;6(2 Pt 2):I198-206. doi: 10.1161/01.hyp.6.2_pt_2.i198.
- Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race-sex and blood pressure level. A further analysis. Hypertension Detection and Follow-up Program Cooperative Group. J Community Health. 1984 Summer;9(4):314-27.
- Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors. The Hypertension Detection and Follow-up Program Cooperative Research Group. Prev Med. 1985 May;14(3):312-35. doi: 10.1016/0091-7435(85)90059-3.
- Bell RL, Curb JD, Friedman LM, Payne GH. Termination of clinical trials: the beta-blocker heart attack trial and the hypertension detection and follow-up program experience. Control Clin Trials. 1985 Jun;6(2):102-11. doi: 10.1016/0197-2456(85)90115-1.
- Lewin A, Blaufox MD, Castle H, Entwisle G, Langford H. Apparent prevalence of curable hypertension in the Hypertension Detection and Follow-up Program. Arch Intern Med. 1985 Mar;145(3):424-7.
- Maxwell MH, Ford CE. Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry. J Cardiovasc Pharmacol. 1985;7 Suppl 2:S5-9. doi: 10.1097/00005344-198507002-00002.
- Heyden S, Borhani NO, Tyroler HA, Schneider KA, Langford HG, Hames CG, Hutchinson R, Oberman A. The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension. J Chronic Dis. 1985;38(4):281-8. doi: 10.1016/0021-9681(85)90073-6.
- Implications of the Hypertension Detection and Follow-up Program. The Hypertension Detection and Follow-up Program Cooperative Group. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):3-10. doi: 10.1016/0033-0620(86)90031-9. No abstract available.
- Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM. The Hypertension Detection and Follow-up Program design, methods, and baseline characteristics and blood pressure response of the study population. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):11-28. doi: 10.1016/0033-0620(86)90032-0. No abstract available.
- Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):29-54. doi: 10.1016/0033-0620(86)90033-2. No abstract available.
- Borhani NO, Blaufox MD, Oberman A, Polk BF. Incidence of coronary heart disease and left ventricular hypertrophy in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):55-62. doi: 10.1016/0033-0620(86)90034-4. No abstract available.
- Daugherty SA, Berman R, Entwisle G, Haerer AF. Cerebrovascular events in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):63-72. doi: 10.1016/0033-0620(86)90035-6. No abstract available.
- Curb JD, Maxwell MH, Schneider KA, Taylor JO, Shulman NB. Adverse effects of antihypertensive medications in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):73-88. doi: 10.1016/0033-0620(86)90036-8. No abstract available.
- Cressman MD, Gifford RW Jr. Clinicians' interpretation of the results and implications of the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):89-97. doi: 10.1016/0033-0620(86)90037-x. No abstract available.
- Abernethy J, Borhani NO, Hawkins CM, Crow R, Entwisle G, Jones JW, Maxwell MH, Langford H, Pressel S. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med. 1986 May-Jun;2(3):123-32.
- Harlan LC, Polk BF, Cooper S, Blaszkowski TP, Ignatius-Smith J, Stromer M, Mull H. Effects of labeling and treatment of hypertension on perceived health. Am J Prev Med. 1986 Sep-Oct;2(5):256-61.
- Williams WR, Schneider KA, Borhani NO, Schnaper HW, Slotkoff LM, Ellefson RD. The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants. Am J Prev Med. 1986 Sep-Oct;2(5):248-55.
- Ford CE, Langford HG, Palmer MJ. Recruitment in the hypertension detection and follow-up program. Control Clin Trials. 1987 Dec;8(4 Suppl):54S-67S. doi: 10.1016/0197-2456(87)90007-9.
- Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman NB. The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. Circulation. 1987 Feb;75(2):340-6. doi: 10.1161/01.cir.75.2.340.
- Educational level and 5-year all-cause mortality in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1987 Jun;9(6):641-6.
- Curb JD, Schneider K, Taylor JO, Maxwell M, Shulman N. Antihypertensive drug side effects in the Hypertension Detection and Follow-up Program. Hypertension. 1988 Mar;11(3 Pt 2):II51-5. doi: 10.1161/01.hyp.11.3_pt_2.ii51.
- Davis BR, Curb JD, Borhani NO, Prineas RJ, Molteni A. Coffee consumption and serum cholesterol in the hypertension detection and follow-up program. Am J Epidemiol. 1988 Jul;128(1):124-36. doi: 10.1093/oxfordjournals.aje.a114935.
- Martin JB, Annegers JF, Curb JD, Heyden S, Howson C, Lee ES, Lee M. Mortality patterns among hypertensives by reported level of caffeine consumption. Prev Med. 1988 May;17(3):310-20. doi: 10.1016/0091-7435(88)90006-0.
- Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1988 Apr 8;259(14):2113-22.
- Cooper SP, Hardy RJ, Labarthe DR, Hawkins CM, Smith EO, Blaufox MD, Cooper CJ, Entwisle G, Maxwell MH. The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-Up Program. Am J Epidemiol. 1988 Feb;127(2):387-403. doi: 10.1093/oxfordjournals.aje.a114812.
- Daugherty SA. Mortality findings beyond five years in the hypertension detection and follow-up program (HDFP). J Hypertens Suppl. 1988 Dec;6(4):S597-601. doi: 10.1097/00004872-198812040-00187.
- Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989 May;13(5 Suppl):I80-93. doi: 10.1161/01.hyp.13.5_suppl.i80.
- Stamler R, Ford CE, Stamler J. Why do lean hypertensives have higher mortality rates than other hypertensives? Findings of the Hypertension Detection and Follow-up Program. Hypertension. 1991 Apr;17(4):553-64. doi: 10.1161/01.hyp.17.4.553.
- Finnerty FA Jr, Shaw LW, Himmelsbach CK. Hypertension in the inner city. II. Detection and follow-up. Circulation. 1973 Jan;47(1):76-8. doi: 10.1161/01.cir.47.1.76. No abstract available.
- Hyden S, Tyroler HA, Hames CG, Bartel A, Thompson JW, Krishan I, Rosenthal T. Diet treatment of obese hypertensives. Clin Sci Mol Med Suppl. 1973 Aug;45 Suppl 1:209s-12. doi: 10.1042/cs045209s. No abstract available.
- Labarthe DR, Hawkins CM, Remington RD. Evaluation of performance of selected devices for measuring blood pressure. Am J Cardiol. 1973 Sep 20;32(4):546-53. doi: 10.1016/s0002-9149(73)80046-3. No abstract available.
- Apostolides A, Hebel JR, McDill MS, Henderson MM. High blood pressure: its care and consequences in urban centres. Int J Epidemiol. 1974 Jun;3(2):105-18. doi: 10.1093/ije/3.2.105. No abstract available.
- Henderson M, Apostolides A, Entwisle G, Hebel R. A study of hypertension in a black urban community: preliminary epidemiologic findings. Prev Med. 1974 Sep;3(3):334-43. doi: 10.1016/0091-7435(74)90045-0. No abstract available.
- Wassertheil-Smoller S, Bell B, Blaufox MD. Computer-aided management of hypertensive patients. Med Care. 1975 Dec;13(12):1044-54. doi: 10.1097/00005650-197512000-00006.
- Wassertheil-Smoller S, Blaufox MD. Planning case-finding activities for a community hypertension-control program. Bull N Y Acad Med. 1976 Jul-Aug;52(6):648-56. No abstract available.
- Langford HG, Watson RL, Thomas JG. Salt intake and the treatment of hypertension. Am Heart J. 1977 Apr;93(4):531-2. doi: 10.1016/s0002-8703(77)80418-3. No abstract available.
- Schlant RC, Felner JL, Heymsfield SB, Gilbert CA, Shulman NB, Tuttle EP, and Blumenstein BA: Echocardiography and Essential Hypertension. Cardiovascular Medicine, 2:477-490, l977.
- Entwisle G, Apostolides AY, Hebel JR, Henderson MM. Target organ damage in black hypertensives. Circulation. 1977 May;55(5):792-6. doi: 10.1161/01.cir.55.5.792.
- Apostolides AY, Entwisle G, Ouellet R, Hebel JR. Improving trend in hypertension control in a black inner city community. Am J Epidemiol. 1978 Feb;107(2):113-9. doi: 10.1093/oxfordjournals.aje.a112513.
- Stamler R, Gosch FC, Stamler J, Lindberg HA, Hilker RR. A hypertension control program based on the workplace. Report on the Chicago Center. J Occup Med. 1978 Sep;20(9):618-25. doi: 10.1097/00043764-197809000-00010.
- Blaufox MD, Wassertheil-Smoller S. Improving blood pressure normalization. Follow-up of hypertension screening and methodologies. N Y State J Med. 1979 Feb;79(2):231-5. No abstract available.
- Ouellet RP, Apostolides AY, Entwisle G, Hebel JR. Estimated community impact of hypertension control in a high risk population. Am J Epidemiol. 1979 May;109(5):531-8. doi: 10.1093/oxfordjournals.aje.a112711. No abstract available.
- Smith EO, Hardy RJ, Cutter GR, Curb JD, and Hawkins CM: Application of Survival Analysis Techniques to Evaluation of Factors Affecting Compliance in a Clinical Trial of Hypertension Control. Controlled Clin Trials, l:59-69, l980.
- Smith EO, Hardy RJ, Cutter GR. A two-compartment regression model applied to compliance in a hypertension treatment program. J Chronic Dis. 1980;33(10):645-51. doi: 10.1016/0021-9681(80)90007-7. No abstract available.
- Smith EO, Hardy RJ, Cooper CJ, Hawkins CM. Two-compartment Markov regression analysis. Comput Programs Biomed. 1980 Dec;12(2-3):129-40. doi: 10.1016/0010-468x(80)90059-8.
- The hypertension detection and follow-up program: Hypertension detection and follow-up program cooperative group. Prev Med. 1976 Jun;5(2):207-15. doi: 10.1016/0091-7435(76)90039-6. No abstract available.
- Blood pressure studies in 14 communities. A two-stage screen for hypertension. JAMA. 1977 May 30;237(22):2385-91. doi: 10.1001/jama.1977.03270490025018.
- Taylor J. The hypertension detection and follow-up program: a progress report. Circ Res. 1977 May;40(5 Suppl 1):I106-9.
- Langford HG. Further analyses of the hypertension detection and follow-up program. Drugs. 1986;31 Suppl 1:23-8. doi: 10.2165/00003495-198600311-00006.
- Race, education and prevalence of hypertension. Am J Epidemiol. 1977 Nov;106(5):351-61.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 4
Plan de datos de participantes individuales (IPD)
Datos del estudio/Documentos
-
Conjunto de datos de participantes individuales
Identificador de información: HDFPComentarios de información: NHLBI proporciona acceso controlado a IPD a través de BioLINCC. El acceso requiere registro, evidencia de aprobación del IRB local o certificación de exención de la revisión del IRB y finalización de un acuerdo de uso de datos.
- Formularios de estudio
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedades cardíacas
-
Region SkaneInscripción por invitaciónInsuficiencia cardíaca New York Heart Association (NYHA) Clase II | Insuficiencia cardíaca New York Heart Association (NYHA) Clase IIISuecia
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University... y otros colaboradoresAún no reclutandoInsuficiencia Cardíaca Sistólica | Insuficiencia cardíaca con fracción de eyección reducida | Insuficiencia cardíaca Clase IV de la New York Heart Association | Insuficiencia cardíaca Clase III de la New York Heart AssociationPolonia
-
Novartis PharmaceuticalsTerminadoPacientes que completaron con éxito el período de tratamiento de 12 meses del estudio principal (receptores de Novo Heart) que estaban interesados en recibir tratamiento con EC-MPS
-
University of WashingtonAmerican Heart AssociationTerminadoInsuficiencia cardíaca, congestiva | Alteración mitocondrial | Insuficiencia cardíaca Clase IV de la New York Heart AssociationEstados Unidos